ArticleFrontiers in oncology2025
Nontargeted metabolomics uncovering metabolite signatures in glioblastoma: a preliminary study on candidate biomarker discovery for IDH subtyping and survival prediction.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glioblastoma region-specific metabolic signatures reflect patient survival duration.Journal of neuro-oncology · 2026Article
- Machine Learning-Driven Metabolomic Biomarker Discovery in Glioblastoma: Advances, Challenges, and Future Directions.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, there are no established tumor-derived metabolic biomarkers in clinical practice that can simultaneously differentiate among nontumorous brain tissues, isocitrate dehydrogenase (IDH) wild-type glioblastomas (GBMs), and IDH mutant GBMs, or accurately predict patient survival. The aim of this study was to identify GBM biomarkers for molecular classification and survival prediction via nontargeted metabolomics. Methods: Brain tissue samples from nontumors, IDH-mutant GBMs, and IDH-wild-type GBMs were analyzed via liquid chromatography-mass spectrometry (LC-MS). Metabolites for molecular classification and survival prediction were identified via sparse partial least-squares discriminant analysis (sPLS-DA) and extreme gradient boosting (XGBoost) models, respectively. Both sets of metabolites were then validated via bootstrap resampling. The biomarkers for survival prediction were further validated using an independent metabolomics dataset. Results: In total, 185 human-derived metabolites were identified with high confidence levels. Two non-overlapping sets of 11 candidate biomarkers for molecular subtyping and survival prediction were screened out. In the validation models for molecular subtyping, the random forest model achieved the highest accuracy (0.787, 95% CI: 0.780-0.795) and a Kappa value of 0.681. The Cox proportional hazards regression model established based on cholic acid and citrulline had an AUC of 0.942 (95% CI: 0.920-0.956) at 84 days and an AUC of 0.812 (95% CI: 0.746-0.826) at 297 days. Conclusion: This exploratory study identified potential metabolic biomarkers for GBM subtyping and prognosis prediction. However, further validation in large-scale clinical studies and mechanistic investigations are needed to confirm their applicability and reliability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.